UK-based Ada Lovelace Institute is gathering evidence on the legal, ethical, social, and health challenges of deploying digital health passports and COVID status apps ahead of an upcoming report aimed at guiding government rollouts.
On Tuesday, the British think tank on data, AI, and society put out an open call to “public health officials, civil society organizations, researchers and interested citizens from across the world” to present evidence on the potential risks and benefits that come with implementing vaccine passports and COVID status apps.
“The evidence review will begin work in January 2021 with a call for evidence and a series of public events focused on the history of vaccine certifications, the technical design for digital certification regimes, and the ethical, health and legal challenges they may pose.”
As part of the assessment, the Ada Lovelace Institute is looking to gather evidence on a series of topics as they relate to the rollouts of digital health passports and COVID status apps, including:
Source: Ada Lovelace Institute
Evidence will be reviewed by an “independent panel,” and the institute will be publishing a series of short reports from each of the public events.
“A report designed to provide guidance to the UK, and other national governments, on the potential roll-out of digital vaccine certification schemes and understand which red lines not to cross and where to focus regulatory attention” — Ada Lovelace Institute
Following the conclusion of the evidence review, a forthcoming report will be issued “to provide guidance to the UK, and other national governments, on the potential roll-out of digital vaccine certification schemes and understand which red lines not to cross and where to focus regulatory attention.”
In April, 2020, the British think tank gathered evidence for a similar report on contact tracing called “Exit through the App Store?” — in which they also explored the concept of digital immunity certification.
The report concluded that back in April, there was “no credible basis for establishing a comprehensive regime of immunity certification” due to an “insufficient understanding of immunity” and having “no robust scientific means of testing for immunity.”
This week, the Ada Lovelace Institute launched its latest open call for evidence on digital health passports and COVID status apps on the same day that British media reported that the government had begun trialing digital COVID-19 vaccine passports for those who had already been vaccinated in the UK.
The digital passport being trialed is an app developed by biometrics firm iProov and cybersecurity firm Mvine.
“Though the Department of Health said that there were ‘no plans’ to introduce vaccine passports, the Government’s own science and research funding agency Innovate UK has already pumped £75,000 into the project,” The Daily Mail reported.
With ethical governance, digital health passports, immunity passports, and COVID status apps have the potential to ease society towards safely opening up movement, travel, and other activities.
At the same time, the personal data collected faces the ever-present risk of being compromised by cyber criminals, abused by law enforcement and governments, or exploited by third-party vendors.
Correction: A previous version of this story stated, “Though the Department of Health denied that there were ‘no plans’ to introduce vaccine passports, the Government’s own science and research funding agency Innovate UK has already pumped £75,000 into the project.”
The quote has been corrected in story above.
In the late 19th Century, physicians began inserting hollow tubes equipped with small lights into…
This year wasn’t exactly what the video gaming industry expected — it declined by 7%…
By Oren Askarov, Growth & Operations Marketing Director at SQream Becoming “data-driven” has become a…
Horasis Asia Meeting, led by German entrepreneur Frank Jurgen-Richter, will take place this year on the…
Techstars is one of the world's most recognized startup organizations, helping to support countless founders…
Article by Vikram (V) Venugopal, General Manager, VP BioPharma at Prezent, Partner at Prezentium Biotech…
View Comments